# Niranjan Sardesai

> Niranjan Sardesai is the founder, president and CEO of Geneos Therapeutics, a Plymouth Meeting, Pennsylvania biotech building personalized DNA-based cancer vaccines that are custom-designed to each patient's own tumor mutations. A Caltech-trained chemist with a Wharton MBA, he spent years as COO helping build Inovio Pharmaceuticals into a Phase III immunotherapy company before spinning out Geneos in 2016. Under his leadership Geneos published a landmark Nature Medicine paper in 2024 showing its neoantigen vaccine drove complete responses in advanced liver cancer, with some patients reaching multi-year, recurrence-free survival.

- **Role:** Founder, President & CEO at Geneos Therapeutics
- **Organizations:** Geneos Therapeutics, Inovio Pharmaceuticals, Fujirebio Diagnostics
- **Nationality:** American
- **Education:** PhD in Chemistry, California Institute of Technology, MBA (Entrepreneurship & Finance), The Wharton School, University of Pennsylvania
- **Known for:** Founded Geneos Therapeutics and its proprietary GT-EPIC personalized neoantigen vaccine platform, Led publication of GT-30 Phase 1/2 hepatocellular carcinoma trial in Nature Medicine (2024), Delivered complete responses and a reported 30.6% objective response rate in advanced liver cancer, a notoriously immune-cold tumor

## Career timeline

- **pre-2000s** — Director of Research and Development at Fujirebio Diagnostics
- **2000s-2016** — Rose to Chief Operating Officer at Inovio Pharmaceuticals, helping build it into a Phase III cancer and infectious disease immunotherapy company
- **2016** — Founded Geneos Therapeutics to develop personalized neoantigen cancer vaccines
- **2022** — Announced positive clinical data and complete responses in the GT-30 liver cancer trial
- **2023-09** — Geneos raised a $5M Series A round (total funding reported near $60M)
- **2024-04** — Published GT-30 Phase 1/2 results in Nature Medicine
- **2025-09** — Reported glioblastoma and liver cancer patients reaching five-plus years of durable recurrence-free survival on monotherapy

## Achievements

- Founded Geneos Therapeutics and its proprietary GT-EPIC personalized neoantigen vaccine platform
- Led publication of GT-30 Phase 1/2 hepatocellular carcinoma trial in Nature Medicine (2024)
- Delivered complete responses and a reported 30.6% objective response rate in advanced liver cancer, a notoriously immune-cold tumor
- As COO, helped build Inovio Pharmaceuticals into a Phase III immunotherapy company
- Authored over 120 peer-reviewed manuscripts and holds multiple patents
- Named by PharmaVoice as one of the 100 most influential and inspirational leaders in life sciences (2015)
- Recipient of the Shils-Zeidman Award in Entrepreneurship; fellowships from Scripps Research Institute and MIT

## Latest updates

- **2025-09** — Geneos reported glioblastoma and advanced liver cancer patients on its personalized immunotherapy monotherapy reaching five-plus years of durable recurrence-free survival.
- **2024-04** — GT-30 Phase 1/2 results published in Nature Medicine, showing complete responses in advanced hepatocellular carcinoma.

## Links

- Website: https://geneostx.com
- LinkedIn: http://www.linkedin.com/in/niranjan-sardesai-7645131

---

Profile page: https://yespress.io/niranjan-sardesai
Published by YesPress — https://yespress.io
Last updated: 2026-07-01